A federal program aimed at bringing down what state Medicaid agencies pay for prescription drugs has moved from pledge to paperwork, and the clock is now running for the states still on the sidelines. The Centers for Medicare & Medicaid Services said this week that forty states and Puerto Rico have signed formal agreements to join the federal government’s most-favored-nation pricing model for Medicaid, while every other state and the District of Columbia has at least applied. The remaining jurisdictions have until the end of the month to finalize the same agreement, and the outcome will shape prescription drug budgets that support long-term care, home health services and daily medication access for millions of low-income and older Medicaid enrollees.
Forty State Signatures Now on File With CMS
CMS announced on September 18 that it has collected signed participation agreements from forty states and Puerto Rico for the GENErating cost Reductions fOr U.S. Medicaid initiative, known by its acronym, GENEROUS. All fifty states, the District of Columbia and Puerto Rico had already applied to the model, but an application alone does not bind a state’s Medicaid program to the new pricing terms; only a signed agreement does that. CMS set September 30, 2026, as the deadline for the remaining states to complete that step, so the list of committed states could still grow before the month is out. GENEROUS launched in January 2026 and is built to run for five years, meaning a state that signs after the deadline is not locked out of the model altogether, but it does start collecting rebates later than the states that have already signed.
Free prescription checklist: When a drug’s price or coverage rule changes, the next refill is where it shows up. Get the free coverage and pharmacy checklist.
How A Manufacturer Rebate Becomes A State Medicaid Savings
The mechanics behind the signature count matter as much as the number itself. Under the agreements CMS is finalizing, participating drug manufacturers agree to make covered outpatient drugs available to a state’s Medicaid program at most-favored-nation pricing, meaning the price cannot exceed what those same drugs sell for in other wealthy countries. When the price a state actually pays still runs higher than that international benchmark, the state invoices the manufacturer directly for a supplemental rebate to close the gap. CMS monitors the resulting pricing data for accuracy and then takes a share of the savings by reducing the federal government’s portion of that state’s Medicaid drug spending, a structure the agency lays out on the program’s official model page. None of that rebate flow exists for a state that has only applied; the pricing terms take effect once a state’s agreement is signed, not before.
A $64.3 Billion Projection, Not Yet a Booked Savings Figure
CMS is projecting that the GENEROUS Model will save an estimated $64.3 billion in taxpayer dollars over the next ten years once every state has signed and the rebate structure is fully running. The White House, in a companion release issued the same day, put the number at “nearly $65 billion” in Medicaid drug savings once all fifty states, the District of Columbia and Puerto Rico are participating, a figure that lines up with the White House’s own accounting of the model. Both numbers describe a ten-year projection tied to a five-year model that only began operating this past January, not money that has already reached a state treasury. CMS Innovation Center Director Abe Sutton framed the intended use of those dollars in the agency’s release, saying the model would let states “invest more in education, infrastructure, and other ways to support Americans with Medicaid” as drug spending falls. Whether an individual state actually realizes its share of that projection depends on manufacturer compliance, accurate pricing data and how many prescriptions its Medicaid enrollees fill, none of which CMS has broken out on a state-by-state basis yet.
Why the Signing Count Matters for Older Medicaid Enrollees
Medicaid is often described as a program for lower-income families with children, but it is also the primary source of long-term care coverage for older Americans who have exhausted savings, and it wraps around Medicare drug coverage for enrollees who qualify for both programs. For that group, a state’s Medicaid drug budget is not an abstract line item: it shapes formulary rules, copay structure and, indirectly, the state funding available for the home health aides and nursing facility services many of those enrollees also rely on. A state that signs onto GENEROUS and starts collecting manufacturer rebates has more room in that budget; a state that has only applied, and has not yet signed, is still operating under the drug pricing arrangements that existed before CMS’s September 18 announcement.
What Missing the September 30 Deadline Would Cost a State’s Medicaid Drug Budget
CMS has not published a list explaining what happens to a state that fails to sign by September 30, but the model’s own design answers part of the question. Most-favored-nation pricing and the supplemental rebates it generates apply only to participating state Medicaid programs, per CMS’s own description of the arrangement; a state agency that never executes an agreement does not collect those manufacturer rebates, and its Medicaid drug budget keeps operating under whatever pricing arrangements were already in place. That distinction matters for the roughly dozen jurisdictions, potentially including the District of Columbia, that had applied to GENEROUS as of September 18 but had not yet joined the forty states and Puerto Rico already under signed agreement. CMS has said its GENEROUS Model page will be the record of which states have signed as the September 30 deadline approaches, making that page, not this week’s announcement, the one to check for any single state’s final status.
Tracking Medicare Drug Costs While Pricing Rules Keep Moving
The GENEROUS Model changes how state Medicaid programs buy drugs, but most older Americans get their prescription coverage through Medicare, not Medicaid, and Medicare runs its own separate set of pricing rules. Those rules include a new annual out-of-pocket cap under Part D and a prior-authorization appeal process that can determine whether a specific drug gets covered at all. Keeping track of which cap applies, which appeal deadline is running, and which state program might help with the rest of a prescription bill is a paperwork problem of its own, one that shifts every time a policy like GENEROUS moves through Washington.
The Medicare Cost & Coverage Protection Kit is a 10-page kit organized around the new Part D out-of-pocket cap and the prior-authorization appeal steps, and it includes a medication and cost tracker along with 51 state Medicare cost-help packs.
Review the Part D cap details and the appeal steps inside The Medicare Cost & Coverage Protection Kit.
This article was researched and drafted with the assistance of AI and reviewed by an editor.
David M. Keller is a finance writer based in Columbus, Ohio, covering personal finance and consumer-focused economic topics. He earned his degree in journalism from Ohio University and began his career reporting on local business and economic trends for a regional media outlet. Since then, he has contributed to a variety of online publications, focusing on clear, practical coverage of topics such as cost of living, debt, and everyday financial decision-making.
